Comparative Performance of a Combined Injectable Contraceptive (50 mg Norethisterone Enanthate Plus 5mg Estradiol Valerate) and a Combined Oral Contraceptive (0.15 mg Levonorgestrel plus 0.03 mg Ethinyl Estradiol) in Adolescents
Author
dc.contributor.author
Molina, Ramiro C.
Author
dc.contributor.author
Sandoval, Jorge Z.
Author
dc.contributor.author
Montero, Adela V.
Author
dc.contributor.author
Oyarzún, Pamela G.
Author
dc.contributor.author
Molina, Temístocles G.
Author
dc.contributor.author
González, Electra A.
Admission date
dc.date.accessioned
2019-03-11T12:56:54Z
Available date
dc.date.available
2019-03-11T12:56:54Z
Publication date
dc.date.issued
2009
Cita de ítem
dc.identifier.citation
Journal of Pediatric and Adolescent Gynecology, Volumen 22, Issue 1, 2018, Pages 25-31
Identifier
dc.identifier.issn
10833188
Identifier
dc.identifier.other
10.1016/j.jpag.2008.07.010
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164699
Abstract
dc.description.abstract
Study Objective: To compare in a regular non-clinical trial experience the efficacy, acceptability, and continuation rates of an injectable contraceptive containing 50 mg norethisterone enanthate plus 5mg estradiol valerate (IC) and an oral contraceptive containing 0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol (OC), among adolescent users. Design: A total of 251 adolescents ages 14-19 were followed during 12 months. The IC group (124 subjects) was studied for 1044 cycles and the OC group (127 subjects) was studied for 1368 cycles. The users were not assigned in a random selection. Information was collected from clinical records. Groups were compared using Pearson chi-square, odds ratio (95% confidence interval), t-test, and proportion difference test. Results: The IC group had significant differences in baseline social risk, confidence, psychiatric problems, consumption of alcohol, and number of sexual partners. At 12 months, the IC group showed significant decrease in weight a
Comparative Performance of a Combined Injectable Contraceptive (50 mg Norethisterone Enanthate Plus 5mg Estradiol Valerate) and a Combined Oral Contraceptive (0.15 mg Levonorgestrel plus 0.03 mg Ethinyl Estradiol) in Adolescents